Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Dalsiclear - 12 weeks

HepatitisC-Abbott-Daclatasvir-60mg-Dalsiclear

Availability: In stock

Special Price $ 449

BRAND : Dalsiclear
STRENGTH : 60mg
INGREDIENT : HepatitisC-Abbott-Daclatasvir-60mg-Dalsiclear
COMPANY NAME : Abbott
COUNT : 28 Tablets



Description of Dalsiclear - 12 weeks

Product Index: Trade name: Dalsiclear Active component: Daclatasvir Strength: 60mg Mfg: Abbott Pack: 28 tablets in a container Category: Anti-viral Description of Dalsiclear 12 weeks Hepatitis C virus is a RNA virus, which causes severe life threatening conditions like; Chronic hepatitis Cirrhosis Hepatocellular carcinoma Dalsiclear is an anti-viral medication, which is available in tablet form. Dalsiclear exhibits its action by prohibiting the non structural 5A protein region of hepatitis C virus Dalsiclear is not monotherapy medicine; it should be combined with other anti-viral drugs for treating chronic hepatitis C infection caused by virus Dalsiclear is available in the strength of 60mg

Pharmacology of Dalsiclear - 12 weeks

Dalsiclear mechanism of action for 12 weeks therapy: Dalsiclear is a NS5A inhibitors, NS5A protein is required for viral multiplication. This NS5A has capability to merge with HCV RNA. There are two specific functions in RNA multiplication which is based on phosphorylated state Cis acting function of phosphorylated NS5A: interfering HCV replication complex Trans acting function: regulate HCV assembly and infectious particle production Dalsiclear will disrupt hyperphosphorylated NS5A protein and mediated with newly formed RNA viral Dalsiclear involved in blockade of intercellular viral RNA synthesis and colony of virion Pharmacokinetic: Dalsiclear 12 weeks Absorption: The peak plasma concentration of Dalsiclear occurs within 2 hours. The mean bioavailability of Dalsiclear is 67% The steady state level reached in 4 days after administration of single dose Distribution: The volume of distribution occurs at 47L. The human plasma protein bound with Dalsiclear with the range of 99% Metabolism: Dalsiclear a CYP3A substrates, it is dominantly metabolized by CYP3A4 isoenzymes High portion of Dalsiclear in plasma is in unchanged form nearly 97% Elimination: The route of elimination of metabolites; Bile: 88%; feces 53% (unchanged form) and 6.6% in unchanged form through urine The mean terminal half life period of Dalsiclear occurs from the range of almost 12 to 15 hours

Indication of Dalsiclear - 12 weeks

Dose & Dosage's of Dalsiclear - 12 weeks

Before initiating the therapy; NS5A resistance testing in HCV genotype 1a infected patients with cirrhosis has been evaluated The usual dose of Dalsiclear is 60mg as a single dose Recommended dosage regimens: Genotype I: Patients suffered by without cirrhosis: Dalsiclear + Sofosbuvir for 12 weeks Compensated cirrhosis (child Pugh A): Dalsiclear + Sofosbuvir for 12 weeks Decompensated cirrhosis (child Pugh B or C): Dalsiclear + Sofosbuvir + ribavirin for 12 weeks Genotype III: Patients without cirrhosis: Dalsiclear with Sofosbuvir for 12 weeks Compensated or decompensated cirrhosis: Dalsiclear with Sofosbuvir + ribavirin for 12 weeks Dose adjustments: While concomitant with strong CYP3A inhibitors: 30mg of Dalsiclear once a day Concomitant with moderate CYP3A inducers & nevirapine: 90mg of Dalsiclear as single dose With strong CYP3A inducers: contraindicated Dalsiclear should be administered with or without food Missed dose: Dalsiclear is a prescription medicine; it should be used only under the guaindance of doctor Do not self medicate If patient fail to take the dose of Dalsiclear tablet, must consult with physician and take the missed dose within the time Otherwise the missed dose should be skipped and follow the regular dosing schedule Do not take overdose

Side Effects of Dalsiclear - 12 weeks

Pharmacological effects: CVS: Bradycardia, heart block, cardiac arrhythmias Liver: Increased AST & ALT, Hyperbilirubinaemia, hepatitis B reactivation Genitourinary: Urinary tract infection Ocular: Dry eye GIT: Abdominal pain, gastro esophageal reflux, vomiting, elevated lipase, flatulence Muscle: Myalgia, arthralgia, back pain Other: Fatigue, asthenia, influenza like symptoms, pyrexia, hot flush, loss of weight Nerve: Headache, migraine, somnolence Dermatological: Rashes, Pruritus, dry skin, alopecia, and Erythema multiforme Psychiatric: Insomnia, irritability, depression, anxiety Blood: Anemia, neutropenia, thrombocytopenia, esinophillia Respiratory: Cough, Nasopharyngitis, dyspnea, nasal congestion, upper respiratory infection Metabolic: Loss of appetite Some common side effects occurred in 12 weeks therapy; Chest pain, dizziness Irregular heart beat Unusual tiredness More common: Headache, nausea

Contraindication of Dalsiclear - 12 weeks

Dalsiclear with ribavirin contraindicated to pregnancy condition Hypersensitivity reaction occur Concurrent use of CYP3A inducers strong with Dalsiclear, contraindicated to the patients

Drug Interaction of Dalsiclear - 12 weeks

Concurrent use of Dalsiclear with some drugs likes; Dalsiclear is an inhibitor of P-glycoprotein transporter, organic anion transporting polypeptide and breast cancer resistance protein; taking Dalsiclear, may elevate exposure to these drugs, which prolong the therapeutic effect Proteases inhibitors: increase effect of concentration of Dalsiclear Efavirenz, etravirine & nevirapine: decrease the effect of concentration of Dalsiclear Amiodarone: serious bradycardia occurs Aprepitant: increase the serum concentration of CYP3A4 substrates Strong inducers of CYP3A causes decreased therapeutic effect of Dalsiclear Strong CYP3A inhibitors: increase the effect of concentration of Dalsiclear HMG CoA reductase: increase the effect of concentration of these lipid lowering drugs

Precaution of Dalsiclear - 12 weeks

There is a risk of adverse effects due to concurrent use of Dalsiclear with some other drugs causes; • Loss of therapeutic effect • Serious life threatening conditions • Symptomatic bradycardia while using with amiodarone • Risk related to ribavirin during combination • Hepatitis B reactivation

Usage & Safety profile of Dalsiclear - 12 weeks Pregnancy & Lactation

During monotherapy: pregnancy category of Dalsiclear -B; it is safe while using alone but under supervision of medical practitioner advice During combination: pregnancy categories with ribavirin-X; causes severe ill effects like fetal harm even to death Breast feeding is safe during monotherapy but in combination with ribavirin breast feeding is not recommended

Storage of Dalsiclear - 12 weeks

Storage: Dalsiclear tablets containers are stored at 25oC (77oF); excursion between 15oC and 30oC (59oF and 86oF) Keep away from heat, moisture and heat